GSK and Alamar will profile more than 60,000 serum samples to see how one diagnosis can hide several diseases.

Eisai’s CTAD slate includes five-year Clarity AD data, a real-world symposium and a look at lecanemab and donanemab dosing.

From brain scans to Super Mario, NeuroAge and TruDiagnostic explain how Younger turns personal health goals into public ...

Built with David Sinclair for Grok Bot, the free multi-agent system turns personal health data into checkable N-of-1 experiments.

SIR2501, a SARM1 blocker with FDA Fast Track status for chemo nerve damage, gets three poster slots in Washington.

A late-breaking slot in Boston will bring fresh data on an experimental drug that aims to turn down tau production in the ...

Ultrahuman’s racing partnership is about more than lap times; the bigger story is the teenage years when female healthspan takes shape.

Employers get one platform for GLP-1 access, hormone therapy and chronic disease coaching, with clinicians still signing off ...

Six-month University of Surrey RCT sees better endothelial function, less arterial stiffness and lower systolic pressure – but lipids unmoved. Professor Christian Heiss and his University of Surrey ...

Alamar and Nightingale will hunt rare, low-level proteins in UK Biobank blood for signs of dementia and Parkinson’s long before diagnosis. The proteins that give the earliest warning of a failing ...

A new review argues that aging has several brakes, not one, and that the way genes are switched may hit the limit first.

Mission Therapeutics has begun a 36-patient Phase 1b study of MTX325, a drug aimed at clearing out damaged mitochondria in ...